Home > Insider Trading > Filing (0001209191-20-001755)

Filing Details

Accession Number:: 0001209191-20-001755
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-01-06 16:15:15
Reporting Period:: 2020-01-02

Accepted Time:: 2020-01-06 16:15:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1654151	Deciphera Pharmaceuticals Inc.	DCPH	Pharmaceutical Preparations (2834)	200299725

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1715153	Arthur James Bristol	C/O Deciphera Pharmaceuticals, Inc. 200 Smith Street Waltham MA 02451		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-01-02	15,553	$1.89	15,553	No	4	M	Direct
Common Stock	Disposition	2020-01-02	9,541	$57.51	6,012	No	4	S	Direct
Common Stock	Disposition	2020-01-02	5,347	$58.08	665	No	4	S	Direct
Common Stock	Disposition	2020-01-02	365	$59.38	300	No	4	S	Direct
Common Stock	Disposition	2020-01-02	300	$61.87	0	No	4	S	Direct
Common Stock	Acquisiton	2020-01-03	7,989	$1.89	7,989	No	4	M	Direct
Common Stock	Disposition	2020-01-03	729	$55.96	7,260	No	4	S	Direct
Common Stock	Disposition	2020-01-03	5,250	$57.21	2,010	No	4	S	Direct
Common Stock	Disposition	2020-01-03	1,810	$58.17	200	No	4	S	Direct
Common Stock	Disposition	2020-01-03	200	$58.72	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-01-02	15,553	$0.00	15,553	$1.89
Common Stock	Stock Option (Right to Buy)	Disposition	2020-01-03	7,989	$0.00	7,989	$1.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
47,855		2025-12-17	No	4	M	Direct
39,866		2025-12-17	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.87 to $57.86, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.87 to $58.73, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.17 to $59.56, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.68 to $62.25, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.55 to $56.38, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.57, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.66 to $58.65, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 to $58.75, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.